138 related articles for article (PubMed ID: 15809742)
1. Oncostatin M signaling in human glioma cell lines.
Krona A; Järnum S; Salford LG; Widegren B; Aman P
Oncol Rep; 2005 May; 13(5):807-11. PubMed ID: 15809742
[TBL] [Abstract][Full Text] [Related]
2. Coexpression of oncostatin M and its receptors and evidence for STAT3 activation in human ovarian carcinomas.
Savarese TM; Campbell CL; McQuain C; Mitchell K; Guardiani R; Quesenberry PJ; Nelson BE
Cytokine; 2002 Mar; 17(6):324-34. PubMed ID: 12061840
[TBL] [Abstract][Full Text] [Related]
3. Oncostatin M induces an acute phase response but does not modulate the growth or maturation-status of liver progenitor (oval) cells in culture.
Matthews VB; Knight B; Tirnitz-Parker JE; Boon J; Olynyk JK; Yeoh GC
Exp Cell Res; 2005 May; 306(1):252-63. PubMed ID: 15878349
[TBL] [Abstract][Full Text] [Related]
4. Oncostatin M-specific receptor expression and function in regulating cell proliferation of normal and malignant mammary epithelial cells.
Liu J; Hadjokas N; Mosley B; Estrov Z; Spence MJ; Vestal RE
Cytokine; 1998 Apr; 10(4):295-302. PubMed ID: 9617575
[TBL] [Abstract][Full Text] [Related]
5. Divergent effects of oncostatin M on astroglioma cells: influence on cell proliferation, invasion, and expression of matrix metalloproteinases.
Chen SH; Gillespie GY; Benveniste EN
Glia; 2006 Jan; 53(2):191-200. PubMed ID: 16206166
[TBL] [Abstract][Full Text] [Related]
6. Growth regulatory pathways in myeloma. Evidence for autocrine oncostatin M expression.
Westendorf JJ; Jelinek DF
J Immunol; 1996 Oct; 157(7):3081-8. PubMed ID: 8816418
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical analysis of the IL-6 family of cytokines and their receptors in benign, hyperplasic, and malignant human prostate.
Royuela M; Ricote M; Parsons MS; García-Tuñón I; Paniagua R; de Miguel MP
J Pathol; 2004 Jan; 202(1):41-9. PubMed ID: 14694520
[TBL] [Abstract][Full Text] [Related]
8. Oncostatin-M induction of vascular endothelial growth factor expression in astroglioma cells.
Repovic P; Fears CY; Gladson CL; Benveniste EN
Oncogene; 2003 Nov; 22(50):8117-24. PubMed ID: 14603252
[TBL] [Abstract][Full Text] [Related]
9. Oncostatin M (OSM) cytostasis of breast tumor cells: characterization of an OSM receptor beta-specific kernel.
Underhill-Day N; Heath JK
Cancer Res; 2006 Nov; 66(22):10891-901. PubMed ID: 17108126
[TBL] [Abstract][Full Text] [Related]
10. Inflammatory cytokines interleukin-6 and oncostatin m induce plasminogen activator inhibitor-1 in human adipose tissue.
Rega G; Kaun C; Weiss TW; Demyanets S; Zorn G; Kastl SP; Steiner S; Seidinger D; Kopp CW; Frey M; Roehle R; Maurer G; Huber K; Wojta J
Circulation; 2005 Apr; 111(15):1938-45. PubMed ID: 15837947
[TBL] [Abstract][Full Text] [Related]
11. Immunocytochemical detection and reverse transcription polymerase chain reaction expression of oncostatin M (OSM) and its receptor (OSM-Rbeta) in human fetal and adult ovaries.
Abir R; Ao A; Jin S; Barnett M; Van den Hurk R; Freimann S; Fisch B
Fertil Steril; 2005 Apr; 83 Suppl 1():1188-96. PubMed ID: 15831292
[TBL] [Abstract][Full Text] [Related]
12. Sodium butyrate sensitizes human glioma cells to TRAIL-mediated apoptosis through inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP.
Kim EH; Kim HS; Kim SU; Noh EJ; Lee JS; Choi KS
Oncogene; 2005 Oct; 24(46):6877-89. PubMed ID: 16007142
[TBL] [Abstract][Full Text] [Related]
13. GP130/OSMR is the only LIF/IL-6 family receptor complex to promote osteoblast differentiation of calvaria progenitors.
Malaval L; Liu F; Vernallis AB; Aubin JE
J Cell Physiol; 2005 Aug; 204(2):585-93. PubMed ID: 15751050
[TBL] [Abstract][Full Text] [Related]
14. Oncostatin M, a multifunctional cytokine.
Tanaka M; Miyajima A
Rev Physiol Biochem Pharmacol; 2003; 149():39-52. PubMed ID: 12811586
[TBL] [Abstract][Full Text] [Related]
15. Expression of oncostatin M and its receptors in normal and cirrhotic human liver.
Znoyko I; Sohara N; Spicer SS; Trojanowska M; Reuben A
J Hepatol; 2005 Nov; 43(5):893-900. PubMed ID: 16169119
[TBL] [Abstract][Full Text] [Related]
16. Cell density-dependent regulation of hepatic development by a gp130-independent pathway.
Kojima N; Kinoshita T; Kamiya A; Nakamura K; Nakashima K; Taga T; Miyajima A
Biochem Biophys Res Commun; 2000 Oct; 277(1):152-8. PubMed ID: 11027656
[TBL] [Abstract][Full Text] [Related]
17. Loss of oncostatin M receptor beta in metastatic melanoma cells.
Lacreusette A; Nguyen JM; Pandolfino MC; Khammari A; Dreno B; Jacques Y; Godard A; Blanchard F
Oncogene; 2007 Feb; 26(6):881-92. PubMed ID: 16909117
[TBL] [Abstract][Full Text] [Related]
18. The gp130 ligand oncostatin M regulates tissue inhibitor of metalloproteinases-1 through ERK1/2 and p38 in human adult cardiac myocytes and in human adult cardiac fibroblasts: a possible role for the gp130/gp130 ligand system in the modulation of extracellular matrix degradation in the human heart.
Weiss TW; Kvakan H; Kaun C; Zorn G; Speidl WS; Pfaffenberger S; Maurer G; Huber K; Wojta J
J Mol Cell Cardiol; 2005 Sep; 39(3):545-51. PubMed ID: 15890357
[TBL] [Abstract][Full Text] [Related]
19. Significant inhibition of TRAIL-mediated fibroblast-like synovial cell apoptosis by IFN-gamma through JAK/STAT pathway by translational regulation.
Tamai M; Kawakami A; Tanaka F; Miyashita T; Nakamura H; Iwanaga N; Izumi Y; Arima K; Aratake K; Huang M; Kamachi M; Ida H; Origuchi T; Eguchi K
J Lab Clin Med; 2006 Apr; 147(4):182-90. PubMed ID: 16581346
[TBL] [Abstract][Full Text] [Related]
20. Expression of tumor necrosis factor alpha, TNF-related apoptosis-inducing ligand, and their associated molecules in ameloblastomas.
Kumamoto H; Ooya K
J Oral Pathol Med; 2005 May; 34(5):287-94. PubMed ID: 15817072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
